DK1888614T3 - Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre - Google Patents
Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyreInfo
- Publication number
- DK1888614T3 DK1888614T3 DK06763188.7T DK06763188T DK1888614T3 DK 1888614 T3 DK1888614 T3 DK 1888614T3 DK 06763188 T DK06763188 T DK 06763188T DK 1888614 T3 DK1888614 T3 DK 1888614T3
- Authority
- DK
- Denmark
- Prior art keywords
- beta
- alkyl
- dihydroxy
- 5beta
- 6alpha
- Prior art date
Links
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 title 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Seasonings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000912A ITMI20050912A1 (it) | 2005-05-19 | 2005-05-19 | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| PCT/EP2006/062446 WO2006122977A2 (en) | 2005-05-19 | 2006-05-19 | PROCESS FOR PREPARING 3α(β)-7α(β)-DIHYDROXY-6α(β)-ALKYL-5β-CHOLANIC ACID |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1888614T3 true DK1888614T3 (da) | 2010-05-10 |
Family
ID=35841713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06763188.7T DK1888614T3 (da) | 2005-05-19 | 2006-05-19 | Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7994352B2 (da) |
| EP (1) | EP1888614B1 (da) |
| JP (1) | JP5127700B2 (da) |
| CN (1) | CN101203526B (da) |
| AT (1) | ATE453657T1 (da) |
| AU (1) | AU2006248906B2 (da) |
| CA (1) | CA2608539C (da) |
| DE (1) | DE602006011457D1 (da) |
| DK (1) | DK1888614T3 (da) |
| ES (1) | ES2338698T3 (da) |
| IT (1) | ITMI20050912A1 (da) |
| WO (1) | WO2006122977A2 (da) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1392714B1 (en) | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for fxr |
| SI2712617T1 (sl) | 2004-03-12 | 2017-01-31 | Intercept Pharmaceuticals, Inc. | Zdravljenje fibroze z uporabo Fxr ligandov |
| US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| EA017714B1 (ru) | 2007-01-19 | 2013-02-28 | Интерсепт Фармасьютикалз, Инк. | Модуляторы tgr5 и способы их применения |
| CA2732323C (en) | 2008-07-30 | 2017-06-27 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| PL2698375T3 (pl) | 2008-11-19 | 2018-08-31 | Intercept Pharmaceuticals, Inc. | Modulatory TGR5 i sposób ich zastosowania |
| CA2746778C (en) | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| SG10201607230SA (en) * | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| AU2013352288B2 (en) | 2012-11-28 | 2017-11-23 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| CN112220797B (zh) | 2013-11-22 | 2023-11-03 | 米纳治疗有限公司 | C/EBPα组合物和使用方法 |
| PT3149019T (pt) * | 2014-05-29 | 2020-02-19 | Bar Pharmaceuticals S R L | Derivados de colano para utilização no tratamento e/ou na prevenção de doenças mediadas por fxr e tgr5/gp-bar1 |
| CN106459136B (zh) * | 2014-09-28 | 2018-06-26 | 江苏盛迪医药有限公司 | 一种奥贝胆酸的制备方法 |
| CN105585603B (zh) * | 2014-10-21 | 2019-05-24 | 重庆医药工业研究院有限责任公司 | 一种制备奥贝胆酸中间体的方法 |
| SG11201703717SA (en) | 2014-11-06 | 2017-06-29 | Enanta Pharm Inc | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| CN105669811B (zh) * | 2014-11-17 | 2020-09-04 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
| ES2748692T3 (es) * | 2014-11-19 | 2020-03-17 | Nzp Uk Ltd | Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides |
| PL3221332T3 (pl) * | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr |
| EA033427B1 (ru) * | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| KR102527821B1 (ko) * | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
| KR20170099909A (ko) | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| CN104558086B (zh) * | 2014-12-25 | 2016-10-05 | 康美（北京）药物研究院有限公司 | 一种5β-3α,7α-二羟基-6α-乙基-胆烷酸的制备方法 |
| CN105777835B (zh) * | 2014-12-25 | 2020-02-14 | 重庆药友制药有限责任公司 | 一种制备鹅去氧胆酸类似物的方法 |
| CN105859814A (zh) * | 2015-01-23 | 2016-08-17 | 江苏奥赛康药业股份有限公司 | 一种奥贝胆酸化合物及其药物组合物 |
| BR112017016766B1 (pt) | 2015-02-06 | 2023-11-07 | Intercept Pharmaceuticals, Inc | Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática |
| CN107249594A (zh) | 2015-02-11 | 2017-10-13 | 英安塔制药有限公司 | 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| CN105985395A (zh) * | 2015-02-13 | 2016-10-05 | 江苏奥赛康药业股份有限公司 | 一种奥贝胆酸化合物及含有该化合物的药物组合物 |
| SG10201910670RA (en) | 2015-03-31 | 2020-01-30 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| MA41083A1 (fr) | 2015-04-07 | 2018-05-31 | Intercept Pharmaceuticals Inc | Compositions pharmaceutiques pour thérapie combinée |
| CN105777836A (zh) * | 2015-04-09 | 2016-07-20 | 厦门蔚扬药业有限公司 | 奥贝胆酸的多晶型物及其制备方法 |
| CN106256833B (zh) * | 2015-06-19 | 2019-01-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 制备3,7-二(三甲基硅基氧基)-6-烯-5β-胆烷-24-酸甲酯的方法 |
| CN105294801A (zh) * | 2015-07-02 | 2016-02-03 | 扬子江药业集团南京海陵药业有限公司 | 6-乙基鹅去氧胆酸异构体的合成及其分离测定方法 |
| CZ2015504A3 (cs) | 2015-07-16 | 2017-01-25 | Zentiva, K.S. | Krystalické formy obeticholové kyseliny |
| CN106397522A (zh) * | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN105175473B (zh) * | 2015-08-19 | 2018-12-21 | 丽珠医药集团股份有限公司 | 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途 |
| CN105085597B (zh) * | 2015-08-28 | 2017-03-29 | 成都百裕制药股份有限公司 | 一种无定型奥贝胆酸的制备方法 |
| CN106478756A (zh) * | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| HK1254056A1 (zh) | 2015-09-21 | 2019-07-12 | 英特塞普特医药品公司 | 促进肝再生的方法 |
| CN108350020A (zh) | 2015-09-24 | 2018-07-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
| CN106589038A (zh) * | 2015-10-15 | 2017-04-26 | 重庆医药工业研究院有限责任公司 | 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法 |
| CN106632564B (zh) * | 2015-10-30 | 2021-04-13 | 苏州泽璟生物制药股份有限公司 | 奥贝胆酸盐及其无定形物和药物组合物 |
| EP3370728A4 (en) | 2015-11-06 | 2019-07-10 | Intercept Pharmaceuticals, Inc. | PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID AND DERIVATIVES THEREOF |
| CN106749466B (zh) * | 2015-11-23 | 2019-05-21 | 南京济群医药科技股份有限公司 | 一种高纯度奥贝胆酸的制备方法 |
| CN105315320B (zh) * | 2015-11-30 | 2017-03-08 | 山东省药学科学院 | 一种制备奥贝胆酸的方法 |
| CN106810586A (zh) * | 2015-12-01 | 2017-06-09 | 中美华世通生物医药科技（武汉）有限公司 | 奥贝胆酸晶型ⅱ及其制备方法和用途 |
| CN105481925B (zh) * | 2015-12-17 | 2018-06-22 | 南京济群医药科技股份有限公司 | 一种奥贝胆酸及其中间体的制备方法 |
| WO2017111979A1 (en) * | 2015-12-22 | 2017-06-29 | Intercept Pharmaceuticals, Inc. | Polymorphic crystalline forms of obeticholic acid |
| CN105646633B (zh) * | 2016-01-22 | 2020-05-26 | 南京长澳医药科技有限公司 | 一种制备奥贝胆酸1型的方法 |
| US11168107B2 (en) | 2016-02-10 | 2021-11-09 | Dr. Reddy's Laboratories Limited | Amine salt of obeticholic acid |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| CN105585605A (zh) * | 2016-03-15 | 2016-05-18 | 成都市新功生物科技有限公司 | 一种奥贝胆酸中间体的合成方法 |
| CN105541953B (zh) * | 2016-03-15 | 2017-11-21 | 成都市新功生物科技有限公司 | 一种高纯度奥贝胆酸的重结晶纯化方法 |
| CN109311933A (zh) | 2016-04-04 | 2019-02-05 | 迪法玛弗朗西斯有限公司 | 制备法尼醇x受体激动剂的方法 |
| KR102377338B1 (ko) | 2016-04-13 | 2022-03-21 | 인터셉트 파마슈티컬즈, 인크. | 암의 치료 방법 |
| TW201738254A (zh) * | 2016-04-19 | 2017-11-01 | 英特賽普醫藥品公司 | 奧貝膽酸及其衍生物之製備方法 |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| CN107400154A (zh) * | 2016-05-18 | 2017-11-28 | 北京凯因科技股份有限公司 | 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法 |
| GB201608779D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CN106046094A (zh) * | 2016-05-30 | 2016-10-26 | 福建广生堂药业股份有限公司 | 一种奥贝胆酸二聚体杂质及其制备方法 |
| WO2017207648A1 (en) | 2016-05-31 | 2017-12-07 | Bionice, S.L.U | Process and intermediates for the preparation of obeticholic acid and derivatives thereof |
| US10875887B2 (en) | 2016-06-01 | 2020-12-29 | Dr. Reddy's Laboratories Limited. | Process for preparation of obeticholic acid |
| CN106083971B (zh) * | 2016-06-17 | 2017-11-14 | 苏州敬业医药化工有限公司 | 一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法 |
| CZ2016385A3 (cs) | 2016-06-28 | 2018-01-10 | Zentiva, K.S. | Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny |
| CA3027761A1 (en) * | 2016-07-13 | 2018-01-18 | Jiangsu Hengrui Medicine Co., Ltd. | Method for manufacturing obeticholic acid and intermediate thereof |
| CN107663221A (zh) * | 2016-07-27 | 2018-02-06 | 南京长澳医药科技有限公司 | 一种奥贝胆酸的制备方法 |
| CN106279335A (zh) * | 2016-08-12 | 2017-01-04 | 齐鲁制药有限公司 | 一种制备奥贝胆酸及其中间体的方法 |
| EP3287467A1 (en) | 2016-08-22 | 2018-02-28 | ratiopharm GmbH | Preparation of obeticholic acid comprising continuous flow process steps |
| CN109641934B (zh) * | 2016-09-20 | 2021-07-02 | 江苏豪森药业集团有限公司 | 胆酸衍生物游离碱，晶型及其制备方法和应用 |
| CN106478757B (zh) * | 2016-09-27 | 2019-01-18 | 华南理工大学 | 一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法 |
| CN107936078A (zh) * | 2016-10-13 | 2018-04-20 | 上海科胜药物研发有限公司 | 一种制备奥贝胆酸的新方法 |
| CN108070014A (zh) * | 2016-11-08 | 2018-05-25 | 北京藏卫信康医药研发有限公司 | 一种化合物的制备方法及其在制备奥贝胆酸中的应用 |
| JP7057783B2 (ja) * | 2016-11-29 | 2022-04-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | スルホニル尿素胆汁酸誘導体の調製方法 |
| CN108117579A (zh) * | 2016-11-29 | 2018-06-05 | 昆明积大制药股份有限公司 | 奥贝胆酸及其中间体的制备方法 |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| CN108456238A (zh) * | 2017-02-20 | 2018-08-28 | 浙江京新药业股份有限公司 | 奥贝胆酸衍生物及奥贝胆酸的制备方法 |
| EP3585374B1 (en) | 2017-02-21 | 2023-07-19 | Genfit | Combination of a ppar agonist with a fxr agonist |
| BR112019020780A2 (pt) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
| JP6987967B2 (ja) * | 2017-04-20 | 2022-01-05 | デーウン・バイオ・インコーポレイテッド | 連続フロー反応を利用した胆汁酸誘導体の製造方法 |
| CN107298694A (zh) * | 2017-04-21 | 2017-10-27 | 华东师范大学 | 奥贝胆酸的合成方法及其中间体 |
| CZ2017298A3 (cs) | 2017-05-26 | 2018-12-05 | Zentiva, K.S. | Amorfní formy obeticholové kyseliny |
| EP3431486A1 (en) | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| US11161872B2 (en) | 2017-08-03 | 2021-11-02 | Medytox Inc. | Methods for preparing bile acids |
| WO2019048631A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE |
| CN108299539B (zh) * | 2018-03-09 | 2021-07-06 | 中山百灵生物技术股份有限公司 | 利用连续流微反应器生产6-亚乙基鹅去氧胆酸的方法 |
| CN110655550A (zh) * | 2018-06-29 | 2020-01-07 | 江苏海悦康医药科技有限公司 | (E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法 |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| WO2020039449A1 (en) | 2018-08-24 | 2020-02-27 | Solara Active Pharma Sciences Limited | An improved process for the preparation of obeticholic acid and intermediates used in the process thereof |
| CN109485686B (zh) * | 2018-12-27 | 2021-08-27 | 重庆华邦胜凯制药有限公司 | 一种提高琥珀酸甲泼尼龙杂质合成中关键中间体6β含量的方法 |
| CN111718388A (zh) | 2019-03-19 | 2020-09-29 | 苏州泽璟生物制药股份有限公司 | 鹅去氧胆酸衍生物的制备方法 |
| JP2022536060A (ja) | 2019-05-30 | 2022-08-12 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物 |
| CN112898369B (zh) * | 2019-12-04 | 2024-09-17 | 博瑞生物医药（苏州）股份有限公司 | 用于制备奥贝胆酸的方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3366932D1 (en) | 1982-07-29 | 1986-11-20 | Lehner Ag | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
| IT1206112B (it) | 1983-04-29 | 1989-04-14 | Lehner Ag | Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
| IT1212835B (it) | 1983-08-18 | 1989-11-30 | Lehner Ag | Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
| US4892868A (en) | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
| IT1196377B (it) | 1984-12-21 | 1988-11-16 | Lehner Ag | Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| IT1223313B (it) | 1987-10-20 | 1990-09-19 | Gipharmex Spa | Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono |
| US5175320A (en) | 1989-04-17 | 1992-12-29 | Giuliani S.P.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
| IT1229570B (it) | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| ATE121080T1 (de) | 1989-12-13 | 1995-04-15 | Mitsubishi Chem Corp | Pyrazolylacrylsäure-derivate, verwendbar als systemische fungiziden in pflanzen- und materialschutz. |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| JP2000514807A (ja) | 1996-07-12 | 2000-11-07 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | レプチン耐性の新規な治療 |
| US6008237A (en) | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| AU759255B2 (en) | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| EP1137940A4 (en) | 1998-10-23 | 2004-06-02 | Glaxo Group Ltd | METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS |
| ES2326850T3 (es) | 1998-12-23 | 2009-10-20 | Glaxo Group Limited | Ensayos para ligandos de receptores nucleares. |
| AU2409600A (en) | 1999-01-07 | 2000-07-24 | Tularik Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
| WO2000057915A1 (en) | 1999-03-26 | 2000-10-05 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
| EP1473042B1 (en) | 1999-03-26 | 2006-06-21 | City of Hope | Screening for FXR receptor modulators |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| US6906057B1 (en) | 1999-06-11 | 2005-06-14 | Allergan, Inc. | Methods for modulating FXR receptor activity |
| EP1185277B1 (en) | 1999-06-11 | 2005-10-26 | Allergan, Inc. | Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer |
| US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| JP2003525217A (ja) | 1999-10-22 | 2003-08-26 | メルク エンド カムパニー インコーポレーテッド | 肥満治療用薬剤 |
| US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| US20020119958A1 (en) | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
| EP1392714B1 (en) | 2001-03-12 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for fxr |
| WO2002084286A1 (en) | 2001-04-12 | 2002-10-24 | Takeda Chemical Industries, Ltd. | Screening method |
| WO2003015777A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| WO2003016280A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| US20030144360A1 (en) | 2001-11-19 | 2003-07-31 | Allergan Sales, Inc. | Composition and method for modulating BAR/FXR receptor activity |
| WO2003080803A2 (en) * | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
| WO2003086303A2 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| RU2310620C2 (ru) | 2002-06-19 | 2007-11-20 | Аваилвс Корпорейшн | Стеновой материал из искусственного камня |
| EP1562915A1 (en) | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x receptor agonists |
| EP1696910A4 (en) | 2003-09-26 | 2009-12-09 | Smithkline Beecham Corp | COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| SI2712617T1 (sl) | 2004-03-12 | 2017-01-31 | Intercept Pharmaceuticals, Inc. | Zdravljenje fibroze z uporabo Fxr ligandov |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| CA2656320C (en) | 2006-06-27 | 2015-04-28 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions |
| EA017714B1 (ru) | 2007-01-19 | 2013-02-28 | Интерсепт Фармасьютикалз, Инк. | Модуляторы tgr5 и способы их применения |
| EP1947108A1 (en) | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| PL2698375T3 (pl) | 2008-11-19 | 2018-08-31 | Intercept Pharmaceuticals, Inc. | Modulatory TGR5 i sposób ich zastosowania |
-
2005
- 2005-05-19 IT IT000912A patent/ITMI20050912A1/it unknown
-
2006
- 2006-05-19 DE DE602006011457T patent/DE602006011457D1/de active Active
- 2006-05-19 EP EP06763188A patent/EP1888614B1/en active Active
- 2006-05-19 AT AT06763188T patent/ATE453657T1/de active
- 2006-05-19 ES ES06763188T patent/ES2338698T3/es active Active
- 2006-05-19 CN CN2006800170256A patent/CN101203526B/zh not_active Expired - Fee Related
- 2006-05-19 DK DK06763188.7T patent/DK1888614T3/da active
- 2006-05-19 WO PCT/EP2006/062446 patent/WO2006122977A2/en not_active Ceased
- 2006-05-19 US US11/914,559 patent/US7994352B2/en active Active
- 2006-05-19 AU AU2006248906A patent/AU2006248906B2/en not_active Ceased
- 2006-05-19 CA CA2608539A patent/CA2608539C/en active Active
- 2006-05-19 JP JP2008511719A patent/JP5127700B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5127700B2 (ja) | 2013-01-23 |
| WO2006122977A2 (en) | 2006-11-23 |
| AU2006248906B2 (en) | 2012-04-12 |
| CA2608539A1 (en) | 2006-11-23 |
| US7994352B2 (en) | 2011-08-09 |
| US20080214515A1 (en) | 2008-09-04 |
| CN101203526B (zh) | 2012-09-05 |
| WO2006122977A3 (en) | 2007-01-18 |
| ITMI20050912A1 (it) | 2006-11-20 |
| ES2338698T3 (es) | 2010-05-11 |
| CN101203526A (zh) | 2008-06-18 |
| EP1888614B1 (en) | 2009-12-30 |
| CA2608539C (en) | 2013-02-26 |
| AU2006248906A1 (en) | 2006-11-23 |
| EP1888614A2 (en) | 2008-02-20 |
| DE602006011457D1 (de) | 2010-02-11 |
| JP2008540612A (ja) | 2008-11-20 |
| ATE453657T1 (de) | 2010-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1888614T3 (da) | Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre | |
| ES2338590T3 (es) | Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos. | |
| DOP2010000396A (es) | Derivado de uracilo o timina para el tratamiento de hepatitis c | |
| DK1637610T3 (da) | Fremgangsmåde til fremstilling af alkylestere | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| DK2076594T3 (da) | Fremgangsmåde til enzymatisk hydrolyse af forbehandlede lignocellulose-udgangsmaterialer | |
| DK2086944T3 (da) | Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater | |
| DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
| DOP2011000301A (es) | Derivados de azaadamantano y metodos de uso de los mismos | |
| DK1893587T3 (da) | Fremgangsmåde til fremstilling af dihydroquinazoliner | |
| DK1896572T3 (da) | Fremgangsmåde til fremstilling af organotypiske cellekulturer | |
| CO6270227A2 (es) | Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas | |
| EA200702464A1 (ru) | Способы получения фенольных 4-бифенилилазетидин-2-онов | |
| DE602006017918D1 (de) | Verfahren zur Herstellung von Telmisartan | |
| DK2300606T3 (da) | Fremgangsmåde til fremstilling af et kaseinhydrolysat | |
| HN2010001233A (es) | Uso derivados de acido tetramico para controlar nematodos | |
| DK2245001T3 (da) | Fremgangsmåde til fremstilling af 2-fluoracyl-3-amino-acrylsyrederivater | |
| AR058253A1 (es) | Procedimiento para la preparacion de ferri-succinilcaseina | |
| NO20074259L (no) | Fremgangsmate for fremstilling av substituerte benzoksazolforbindelser | |
| DK1831239T3 (da) | Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-lambda-lacton og nøgle-mellemprodukter til denne fremgangsmåde | |
| DK1899454T3 (da) | Serumfrit kulturmedium til fremstilling af rekombinante gonadotropiner | |
| EA200900944A1 (ru) | Новый способ получения кристаллической формы v агомелатина | |
| CO6390054A2 (es) | Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina | |
| BRPI0514053A (pt) | método para aumentar a tolerabilidade das plantas frente ao glifosato | |
| DK1926732T3 (da) | Fremgangsmåde til fremstillingen af carbapenemforbindelser |